1 week ago
1
Richard Drury/DigitalVision via Getty Images
United Therapeutics (NASDAQ:UTHR) announced on Tuesday that a late-stage registrational trial for its lead asset, Tyvaso (treprostinil), has reached its primary goal in treating a lung-scarring disorder known as idiopathic pulmonary fibrosis.
Shares of the company are currently on hold
English (US) ·